

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



国药集团  
SINOPHARM

# 國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.\*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)  
(Stock Code: 01099)

## ANNOUNCEMENT

### PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 28 October 2024 (the “**Announcement**”) in relation to the 2024 third quarterly report of China National Accord Medicines Corporation Ltd. (“**Sinopharm Accord**”), a subsidiary of the Company and whose A shares and B shares are listed on the Shenzhen Stock Exchange (stock code for A shares: 000028; stock code for B shares: 200028).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of Sinopharm Accord for the nine months ended 30 September 2024 as set out in the Announcement.

\* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.

**PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF  
SINOPHARM ACCORD**

*Unit: Yuan  
Currency: RMB*

	<b>Reporting Period (Single Quarter)</b>	<b>Changes in the Reporting Period over the same period of last year</b>	<b>From the beginning of the year to the end of the Reporting Period</b>	<b>Changes from the beginning of the year to the end of the Reporting Period over the same period of last year</b>
Revenue	18,680,373,857.42	2.65%	56,466,354,478.37	-0.21%
Net profit attributable to shareholders of the listed company	322,054,929.13	-10.39%	1,065,542,103.97	-10.43%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	312,760,419.20	-10.17%	1,024,138,901.32	-10.39%
Net cash flow arising from operating activities	—	—	1,281,092,108.09	-12.58%
Basic earnings per share (Yuan/Share)	0.58	-10.77%	1.91	-10.75%
Diluted earnings per share (Yuan/Share)	0.58	-10.77%	1.91	-10.75%
Weighted average return on net assets	1.80%	Decreased by 0.34 percentage point	5.99%	Decreased by 1.19 percentage points
	<b>At the end of the Reporting Period</b>	<b>At the end of last year</b>	<b>Changes in the end of the Reporting Period over the end of last year</b>	
Total assets	51,980,855,572.31	47,571,094,779.26	9.27%	
Equity attributable to shareholders of listed company	18,101,879,082.99	17,414,808,729.06	3.95%	

*Note: "Reporting Period" refers to the three months ended 30 September 2024.*

By order of the Board  
**Sinopharm Group Co. Ltd.**  
**Zhao Bingxiang**  
*Chairman*

Shanghai, the PRC  
28 October 2024

*As at the date of this announcement, the executive director of the Company is Mr. Lian Wanyong; the non-executive directors of the Company are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.*